BL Pharmtech KRX:065170KOSDAQ
비엘팜텍 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked2since Sep 11
In Q2 2026, BL Pharmtech reported revenue of ₩713m, down 60.4% year on year, and an operating loss of ₩483m. BL Pharmtech (비엘팜텍) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals M&A / stake deal Screener
BL Pharmtech quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩713m | -60.4% | −₩483m margin −67.7% | −₩807m |
| Q1 2026 | ₩1.5bn | -49.2% | ₩49m margin 3.2% | ₩523m |
| Q4 2025 derived | ₩810m | -36.8% | −₩1.1bn margin −141.0% | −₩13.8bn |
| Q3 2025 | ₩907m | -64.6% | −₩503m margin −55.4% | −₩1.1bn |
| Q2 2025 | ₩1.8bn | +19.7% | −₩574m margin −31.8% | −₩852m |
| Q1 2025 | ₩3.0bn | -13.6% | −₩605m margin −20.3% | −₩1.1bn |
| Q4 2024 derived | ₩1.3bn | -71.0% | −₩1.6bn margin −123.5% | −₩3.1bn |
| Q3 2024 | ₩2.6bn | -65.1% | −₩106m margin −4.1% | −₩770m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
BL Pharmtech top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.